Since in solid tumors p53 IHC is an accurate and frequently used surrogate marker to assess TP53 mutations, p53 IHC is also frequently used for lymphomas, while in this entity the performance of p53 IHC has currently not been definitively established. The gene discussed is TP53; the disease is lymphoma.